sf0166
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Aug 24, 2016 (NCT02914613)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Vitronectin receptor alphaINHIBITOR
ITGAV inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- sf0166
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02914639 | Phase 1/Phase 2 (Phase 2) | Oct 5, 2016 | SciFluor Life Sciences, Inc. |
| NCT02914613 | Phase 1/Phase 2 (Phase 2) | Aug 24, 2016 | SciFluor Life Sciences, Inc. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SciFluor Life Sciences, Inc. | For profit | 2 | 2 | 1 | 2016 |
1 organizations
Page 1 / 1